Sign in or create an account to add this stock to your watchlist.
About ContraFect (NASDAQ:CFRX)
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300
Debt
Debt-to-Equity RatioN/A
Current Ratio10.63
Quick Ratio10.63
Price-To-Earnings
Trailing P/E Ratio-5.19
Forward P/E Ratio-5.33
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book11.29
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-15,510,000.00
Net MarginsN/A
Return on Equity-87.85%
Return on Assets-45.63%
Miscellaneous
Employees23
Outstanding Shares73,660,000
ContraFect (NASDAQ:CFRX) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How were ContraFect's earnings last quarter?
ContraFect (NASDAQ:CFRX) issued its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.09). View ContraFect's Earnings History.
When is ContraFect's next earnings date?
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include TIGENIX/S (TIG), Achaogen (AKAO), Insys Therapeutics (INSY), Evelo Biosciences (EVLO), Cara Therapeutics (CARA), Mersana Therapeutics (MRSN), Achillion Pharmaceuticals (ACHN), Aurinia Pharmaceuticals (AUPH), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Cytokinetics (CYTK), Concert Pharmaceuticals (CNCE), Zymeworks (ZYME) and ProMetic Life Sciences (PFSCF).
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Dr. Steven C. Gilman, Exec. Chairman, Chief Exec. Officer and Pres (Age 65)
- Ms. Natalie Bogdanos J.D., Gen. Counsel and Corp. Sec. (Age 49)
- Dr. Cara Cassino M.D., Chief Medical Officer and Exec. VP of R&D (Age 56)
- Mr. Michael Messinger CPA, Sr. VP of Fin. (Age 43)
- Ms. Nancy Dong, VP of Fin. & Admin. and Controller (Age 53)
Has ContraFect been receiving favorable news coverage?
Media coverage about CFRX stock has been trending somewhat positive on Saturday, according to Accern. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ContraFect earned a news sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.97 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are ContraFect's major shareholders?
ContraFect's stock is owned by a number of of retail and institutional investors. Top institutional investors include DRW Securities LLC (0.15%), JPMorgan Chase & Co. (0.11%) and Opus Point Partners Management LLC (0.10%). Company insiders that own ContraFect stock include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect.
Which major investors are selling ContraFect stock?
Which major investors are buying ContraFect stock?
CFRX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and DRW Securities LLC. Company insiders that have bought ContraFect stock in the last two years include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Insider Buying and Selling for ContraFect.
How do I buy shares of ContraFect?
Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of CFRX stock can currently be purchased for approximately $1.92.
How big of a company is ContraFect?
ContraFect has a market capitalization of $137.74 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe.
How can I contact ContraFect?
ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]
MarketBeat Community Rating for ContraFect (CFRX)
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
ContraFect (NASDAQ:CFRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | Hold | Hold | Hold |
| Consensus Rating Score: | N/A | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
ContraFect (NASDAQ:CFRX) Consensus Price Target History
ContraFect (NASDAQ:CFRX) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
ContraFect (NASDAQ:CFRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ContraFect (NASDAQ CFRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 59.16%
ContraFect (NASDAQ CFRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/25/2017 | Cara M Cassino | Insider | Buy | 8,000 | $1.24 | $9,920.00 | 8,000 |  |
| 7/25/2017 | Joshua B Muntner | SVP | Buy | 2,000 | $1.24 | $2,480.00 | 2,000 | |
| 7/25/2017 | Sol J Barer | Director | Buy | 40,000 | $1.24 | $49,600.00 | 815,933 | |
| 7/25/2017 | Steven C Gilman | CEO | Buy | 800 | $1.24 | $992.00 | 20,800 | |
| 7/27/2016 | Steven C Gilman | CEO | Buy | 20,000 | $2.48 | $49,600.00 | 20,000 | |
| 11/17/2015 | Daniel Couto | SVP | Sell | 2,872 | $3.81 | $10,942.32 | | |
| 11/3/2015 | Daniel Couto | SVP | Sell | 2,867 | $4.23 | $12,127.41 | 2,872 | |
| 10/20/2015 | Daniel Couto | SVP | Sell | 2,867 | $4.48 | $12,844.16 | 5,739 | |
| 10/6/2015 | Daniel Couto | SVP | Sell | 2,867 | $4.11 | $11,783.37 | 8,606 | |
| 9/22/2015 | Daniel Couto | SVP | Sell | 2,867 | $4.76 | $13,646.92 | 10,773 | |
| 9/8/2015 | Daniel Couto | SVP | Sell | 2,867 | $4.90 | $14,048.30 | 14,340 | |
| 3/2/2015 | Julia P Gregory | CEO | Buy | 11,778 | $4.61 | $54,296.58 | | |
(Data available from 1/1/2013 forward)
ContraFect (NASDAQ CFRX) News Headlines
| Source: |
|
ContraFect (NASDAQ:CFRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ContraFect (NASDAQ:CFRX) Income Statement, Balance Sheet and Cash Flow Statement
ContraFect (NASDAQ CFRX) Stock Chart for Saturday, May, 26, 2018
Loading chart…
